Literature DB >> 3357892

Identification of human immunodeficiency virus subtypes with distinct patterns of sensitivity to serum neutralization.

C Cheng-Mayer1, J Homsy, L A Evans, J A Levy.   

Abstract

The human immunodeficiency virus (HIV) type 1 displays a high degree of genetic variation, especially in the glycoprotein (gp120) domain of the envelope gene. To determine whether this genomic heterogeneity leads to the expression of independent HIV subtypes, 12 sera from HIV type 1 antibody-positive individuals were tested for their ability to neutralize 20 HIV isolates of various origins. Four distinct HIV subtypes with different sensitivity to serum neutralization were identified. These results suggest that a finite number of HIV subtypes exist and that the combined use of selected HIV isolates representing several subtypes may be necessary for the development of an effective vaccine.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3357892      PMCID: PMC280090          DOI: 10.1073/pnas.85.8.2815

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  34 in total

1.  A study of the basic aspects of neutralization of two animal viruses, western equine encephalitis virus and poliomyelitis virus.

Authors:  R DULBECCO; M VOGT; A G STRICKLAND
Journal:  Virology       Date:  1956-04       Impact factor: 3.616

2.  Complete nucleotide sequence of the AIDS virus, HTLV-III.

Authors:  L Ratner; W Haseltine; R Patarca; K J Livak; B Starcich; S F Josephs; E R Doran; J A Rafalski; E A Whitehorn; K Baumeister
Journal:  Nature       Date:  1985 Jan 24-30       Impact factor: 49.962

3.  Differential ability of human immunodeficiency virus isolates to productively infect human cells.

Authors:  L A Evans; T M McHugh; D P Stites; J A Levy
Journal:  J Immunol       Date:  1987-05-15       Impact factor: 5.422

4.  Nucleotide sequence of the AIDS virus, LAV.

Authors:  S Wain-Hobson; P Sonigo; O Danos; S Cole; M Alizon
Journal:  Cell       Date:  1985-01       Impact factor: 41.582

5.  Human immunodeficiency viruses.

Authors:  J Coffin; A Haase; J A Levy; L Montagnier; S Oroszlan; N Teich; H Temin; K Toyoshima; H Varmus; P Vogt
Journal:  Science       Date:  1986-05-09       Impact factor: 47.728

6.  Patterns of antibody response in individuals infected with the human immunodeficiency virus.

Authors:  L Z Pan; C Cheng-Mayer; J A Levy
Journal:  J Infect Dis       Date:  1987-04       Impact factor: 5.226

7.  Neutralization of human T-lymphotropic virus type III by sera of AIDS and AIDS-risk patients.

Authors:  R A Weiss; P R Clapham; R Cheingsong-Popov; A G Dalgleish; C A Carne; I V Weller; R S Tedder
Journal:  Nature       Date:  1985 Jul 4-10       Impact factor: 49.962

8.  High prevalence of antibodies to acquired immune deficiency syndrome (AIDS)-associated retrovirus (ARV) in AIDS and related conditions but not in other disease states.

Authors:  L S Kaminsky; T McHugh; D Stites; P Volberding; G Henle; W Henle; J A Levy
Journal:  Proc Natl Acad Sci U S A       Date:  1985-08       Impact factor: 11.205

9.  Human immunodeficiency virus neutralizing antibodies recognize several conserved domains on the envelope glycoproteins.

Authors:  D D Ho; M G Sarngadharan; M S Hirsch; R T Schooley; T R Rota; R C Kennedy; T C Chanh; V L Sato
Journal:  J Virol       Date:  1987-06       Impact factor: 5.103

10.  Isolation of lymphocytopathic retroviruses from San Francisco patients with AIDS.

Authors:  J A Levy; A D Hoffman; S M Kramer; J A Landis; J M Shimabukuro; L S Oshiro
Journal:  Science       Date:  1984-08-24       Impact factor: 47.728

View more
  48 in total

1.  Changes in the immunogenic properties of soluble gp140 human immunodeficiency virus envelope constructs upon partial deletion of the second hypervariable region.

Authors:  Indresh K Srivastava; Keating VanDorsten; Lucia Vojtech; Susan W Barnett; Leonidas Stamatatos
Journal:  J Virol       Date:  2003-02       Impact factor: 5.103

2.  Isolates of human immunodeficiency virus type 1 from the brain may constitute a special group of the AIDS virus.

Authors:  C Cheng-Mayer; C Weiss; D Seto; J A Levy
Journal:  Proc Natl Acad Sci U S A       Date:  1989-11       Impact factor: 11.205

3.  Synthetic peptides from a conserved region of gp120 induce broadly reactive anti-HIV responses.

Authors:  W J Morrow; W M Williams; A S Whalley; T Ryskamp; R Newman; C Y Kang; S Chamat; H Köhler; T Kieber-Emmons
Journal:  Immunology       Date:  1992-04       Impact factor: 7.397

4.  The effects of cotrimoxazole or tenofovir co-administration on the pharmacokinetics of maraviroc in healthy volunteers.

Authors:  Samantha Abel; Deborah Russell; Lyndsey A Whitlock; Caroline E Ridgway; Gary J Muirhead
Journal:  Br J Clin Pharmacol       Date:  2008-04       Impact factor: 4.335

5.  Differential loss of envelope glycoprotein gp120 from virions of human immunodeficiency virus type 1 isolates: effects on infectivity and neutralization.

Authors:  J A McKeating; A McKnight; J P Moore
Journal:  J Virol       Date:  1991-02       Impact factor: 5.103

Review 6.  B cell responses to HIV and the development of human monoclonal antibodies.

Authors:  J E Boyd; K James
Journal:  Clin Exp Immunol       Date:  1992-05       Impact factor: 4.330

7.  Exploration of antigenic variation in gp120 from clades A through F of human immunodeficiency virus type 1 by using monoclonal antibodies.

Authors:  J P Moore; F E McCutchan; S W Poon; J Mascola; J Liu; Y Cao; D D Ho
Journal:  J Virol       Date:  1994-12       Impact factor: 5.103

8.  Inhibition of HIV replication by CD8+ T cells correlates with CD4 counts and clinical stage of disease.

Authors:  A M Gómez; F M Smaill; K L Rosenthal
Journal:  Clin Exp Immunol       Date:  1994-07       Impact factor: 4.330

9.  Structural modulations of the envelope gp120 glycoprotein of human immunodeficiency virus type 1 upon oligomerization and differential V3 loop epitope exposure of isolates displaying distinct tropism upon virion-soluble receptor binding.

Authors:  L Stamatatos; C Cheng-Mayer
Journal:  J Virol       Date:  1995-10       Impact factor: 5.103

10.  Factors associated with the development of cross-reactive neutralizing antibodies during human immunodeficiency virus type 1 infection.

Authors:  D Noah Sather; Jakob Armann; Lance K Ching; Angeliki Mavrantoni; George Sellhorn; Zachary Caldwell; Xuesong Yu; Blake Wood; Steve Self; Spyros Kalams; Leonidas Stamatatos
Journal:  J Virol       Date:  2008-11-05       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.